middle.news
Actinogen’s November Alzheimer’s Test Enters Its Final Stage
9:57am on Monday 19th of October, 2026 AEDT
•
Biotechnology
Read Story
Actinogen’s November Alzheimer’s Test Enters Its Final Stage
9:57am on Monday 19th of October, 2026 AEDT
Key Points
XanaMIA topline results remain scheduled for November 2026
160 patients enrolled in the open-label extension, with an 87% rollover rate
$15.9 million cash at September end, plus an expected approximately $6 million net R&D rebate
$5.3 million raised through option exercises and underwriting during September
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Actinogen Medical (ASX:ACW)
OPEN ARTICLE